Replimune Group, Inc.

NASDAQ:REPL

12.5 (USD) • At close December 24, 2024
Bedrijfsnaam Replimune Group, Inc.
Symbool REPL
Munteenheid USD
Prijs 12.5
Beurswaarde 941,756,250
Dividendpercentage 0%
52-weken bereik 4.92 - 17
Industrie Biotechnology
Sector Healthcare
CEO Mr. Philip Astley-Sparke F.S.A., FSA
Website https://www.replimune.com

An error occurred while fetching data.

Over Replimune Group, Inc.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus

Vergelijkbare Aandelen

Pulmonx Corporation logo

Pulmonx Corporation

LUNG

6.16 USD

Erasca, Inc. logo

Erasca, Inc.

ERAS

2.57 USD

Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

DSGN

6.35 USD

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

1.21 USD

Theravance Biopharma, Inc. logo

Theravance Biopharma, Inc.

TBPH

9.85 USD

Cross Country Healthcare, Inc. logo

Cross Country Healthcare, Inc.

CCRN

17.97 USD

POINT Biopharma Global Inc. logo

POINT Biopharma Global Inc.

PNT

12.5 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

uniQure N.V. logo

uniQure N.V.

QURE

17.35 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)